Taking stock: where does Europe stand in the elimination of hepatitis B and C?
In 2016, a regional action plan for Europe that aims to contribute to the implementation of the global viral hepatitis elimination strategy was developed by the WHO Regional Office for Europe. In an article published today in Eurosurveillance, the authors take a closer look how Europe is doing according to the ten indicators and targets outlined in this plan. In short: Europe still has some way to go if it wants to eliminate viral hepatitis by 2030.
Hepatitis A Seroprevalence in a population of immigrants at a French vaccination centreArchived
The authors retrospectively analyzed hepatitis A virus (HAV) seroprevalence in travellers who had been born and lived at least 1 year in a developing country, wanted to travel to a hepatitis A endemic area, and consulted at the vaccination centre of the Institut Pasteur of Paris between September 1, 2008 and February 28, 2010. HAV seroprevalence was 82.4 % for a population of 646 immigrants for whom data were available
Universal screening for hepatitis B among pregnant women led to 96% vaccination coverage among newborns of HBsAg positive mothers in DenmarkArchived
Universal screening of pregnant women is feasible and has led to immunisation in nearly all identified cases in Denmark. As a consequence of the study the National Board of Health has made universal HBsAg screening of pregnant women permanent in the country.
Adoption of regional hepatitis action plan by WHO Regional Committee
This first European Action Plan provides an important driver to aid countries in their fight against viral hepatitis, to which ECDC had the opportunity to contribute directly.